Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company developing targeted cancer therapies and advanced cell therapy enhancement platforms, has successfully completed a capital raise totalling approximately $6 million. The Melbourne-based firm announced that the funds were secured through a Share Purchase Plan (SPP) and a follow-on Placement, providing crucial financial backing to advance the ongoing development of its lead candidate, PTX-100. This capital infusion is designed to support the program beyond a critical upcoming Dose Optimisation Committee meeting.
The Share Purchase Plan saw continued support from existing shareholders, contributing approximately $4.8 million to the total raise, specifically $4,798,108 after final reconciliation. Shares under the SPP are expected to be allotted on or about Wednesday, 30th September 2026. The shortfall Placement, which garnered support from sophisticated and professional investors, raised an additional $1,203,699.96. The issue price for shares under both the Placement and the SPP was set at $0.065 (6.5 cents) per share, with approximately 18,518,453 new shares expected to be allotted under the Placement around the same date.
The newly raised capital is set to significantly strengthen Prescient’s cash position, specifically providing additional funding for PTX-100’s continued development past the first Dose Optimisation Committee review, scheduled for December 2026. This committee will recommend the optimal dose for progression and guide the study’s continuation, with the ultimate goal of moving towards regulatory approval and broader patient access for an area of significant unmet medical need. Prescient CEO James McDonnell expressed gratitude to shareholders, stating the raise is an “important step forward, funding the progress of PTX-100 through Phase 2a” and looking ahead to a potential Phase 2b study with registrational potential and eventual commercialisation.
